Dr. McCall began his career as a medicinal chemist with Upjohn and has subsequently held positions with Pharmacia & Upjohn, Pharmacia, and Pfizer. He was director of CNS research with Upjohn, vice president and global head of chemistry for both Pharmacia and Pharmacia & Upjohn, and vice president research with Pfizer. Since starting his own consulting and research company, he has been spending significant time on smaller diseases, particularly Duchenne, SMA, Rett, and PKD. He’s chaired an NINDS development team in the spinal muscular atrophy area, is a member of the NIH Blueprint Steering Committee, and serves as a member of the NIH NeuroNEXT Steering Committee. Dr. McCall serves on nine administrative and scientific advisory boards and co-founded Reveragen, which targets new therapies for muscular dystrophy. His board and scientific advisory board positions include NIH Blueprint, NIH NeuroNEXT, IRSF Foundation, PsychoGenics, Emerald Bioscience, Nimbus, Lycera, Hotspot, Rodin, Reaction Biology, ReveraGen Biopharma, and others. Dr. McCall holds over 70 U.S. patents and has authored or co-authored over 81 reviewed publications.